Aytu BioPharma, Inc. appointed Christopher Brooke as Chief Operating Officer. Mr. Brooke has served as the Company's Executive Vice President, Rare Disease Development since joining the Company in April 2021 upon the acquisition of the global license to AR101 (enzastaurin) from Rumpus Therapeutics. In January 2019, Mr. Brooke co-founded Rumpus to develop new medicines for pediatric onset rare and orphan diseases.

Prior to Rumpus, Mr. Brooke served as Senior Vice President, Corporate Strategy and Development from January 2017 to December 2018 at AmerisourceBergen, a publicly held pharmaceutical wholesale company. Mr. Brooke has over 20 years of general management experience in healthcare across all phases of development and commercialization, holding roles of increasing responsibility at Centocor (Johnson & Johnson), a publicly held pharmaceutical company, and MedImmune (AstraZeneca), a publicly held pharmaceutical company. His rare disease experience includes launching pediatric inflammatory bowel disease indications while at Johnson & Johnson as well as leading the pediatric infectious disease franchise at AstraZeneca.

Mr. Brooke went on to lead the fully integrated Diabetes Division at AstraZeneca. Mr. Brooke has a BA from Colgate University and an MBA from the Wharton School at the University of Pennsylvania. The company announced Appointment of Co-Founder Jarrett Disbrow to newly created role of Chief Business Officer & President, Consumer Health and Promotion of Ryan Selhorn to newly created role of Executive Vice President, Finance and Business Optimization.